COMMUNIQUÉ DE PRESSE publié le 23/05/2024 à 13:00, il y a 5 mois 29 jours CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRÈVE publiée le 24/04/2024 à 13:11, il y a 6 mois 27 jours CureVac annonce ses résultats financiers pour 2023 et des mises à jour stratégiques sur ses activités Technologie ARNm CureVac Collaborations Pharmaceutiques Vaccins Contre L'oncologie Vaccins Prophylactiques
BRÈVE publiée le 24/04/2024 à 13:11, il y a 6 mois 27 jours CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRÈVE publiée le 24/04/2024 à 13:08, il y a 6 mois 27 jours CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
BRÈVE publiée le 24/04/2024 à 13:08, il y a 6 mois 27 jours CureVac commence une étude combinée de phase 1/2 pour le vaccin contre la grippe aviaire H5N1 avec GSK GSK CureVac Étude De Phase 1/2 Grippe H5N1 Vaccin À ARNm
COMMUNIQUÉ DE PRESSE publié le 24/04/2024 à 13:06, il y a 6 mois 27 jours CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update CureVac announces financial results for the fourth quarter and full-year 2023, along with business updates, organizational redesign, collaborations, and appointments Financial Results Business Update Collaborations CureVac Organizational Redesign
BRÈVE publiée le 24/04/2024 à 13:05, il y a 6 mois 27 jours CureVac nomme Thaminda Ramanayake au poste de directrice commerciale Stratégie D'entreprise Biopharmaceutique Technologie ARNm Développement Des Affaires CureVac
BRÈVE publiée le 24/04/2024 à 13:05, il y a 6 mois 27 jours CureVac Appoints Thaminda Ramanayake as New Chief Business Officer Business Development Biopharmaceutical MRNA Technology Corporate Strategy CureVac
COMMUNIQUÉ DE PRESSE publié le 24/04/2024 à 13:03, il y a 6 mois 27 jours CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK CureVac initiates combined Phase 1/2 study with GSK for H5N1 avian influenza vaccine candidate, leveraging mRNA technology for pandemic preparedness MRNA Technology CureVac Phase 1/2 Study GSK Collaboration H5N1 Avian Influenza
COMMUNIQUÉ DE PRESSE publié le 24/04/2024 à 13:00, il y a 6 mois 27 jours CureVac Appoints Thaminda Ramanayake as New Chief Business Officer CureVac appoints Thaminda Ramanayake as Chief Business Officer, bringing extensive biopharma experience. Ramanayake to enhance strategic partnerships and accelerate mRNA therapies Biopharma CureVac Thaminda Ramanayake Chief Business Officer MRNA Therapies
Publié le 21/11/2024 à 06:58, il y a 1 jour 5 heures Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 1 jour 5 heures Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 1 jour 5 heures Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 1 jour 16 heures Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 1 jour 17 heures Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Publié le 22/11/2024 à 09:00, il y a 3 heures 37 minutes Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Publié le 22/11/2024 à 00:00, il y a 12 heures 37 minutes Gratomic Announces Company and Operational Update
Publié le 21/11/2024 à 22:05, il y a 14 heures 32 minutes Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Publié le 21/11/2024 à 21:50, il y a 14 heures 47 minutes Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Publié le 21/11/2024 à 20:15, il y a 16 heures 22 minutes Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Publié le 22/11/2024 à 11:54, il y a 43 minutes PIERER Mobility denies media reports about Mark Mateschitz's participation in PIERER Mobility and KTM
Publié le 22/11/2024 à 11:45, il y a 52 minutes How 5G Transforms Life: A Foreigner's Journey Through East China's Digital Revolution
Publié le 22/11/2024 à 11:21, il y a 1 heure 16 minutes Original-Research: ParTec AG (von First Berlin Equity Research GmbH): Buy
Publié le 22/11/2024 à 11:06, il y a 1 heure 31 minutes Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
